



Your Smile. Our Vision.

## ASX Announcement

16 April 2018

### SDI Limited FDA Approves Riva Star

MELBOURNE, Australia – SDI Limited (ASX: SDI) is pleased to announce that the Federal Drug Administration (FDA) has given registration approval to market Riva Star in the USA, the world's largest dental market.

Riva Star's FDA registration is as a new generation desensitiser that immediately relieves tooth sensitivity. In addition to this announcement of registration approval in the USA, SDI has previously been successful in registering Riva Star in several key Latin American countries including, Brazil, Peru, and Colombia as an anti-caries (decay) agent.

Riva Star's key ingredients are silver diamine fluoride (SDF) and potassium iodide (KI). SDF is an antimicrobial solution which stops decay in teeth. Unlike any other SDF based system, Riva Star's two step global patented procedure minimises the risk of staining the tooth. By applying the KI solution over the SDF, a precipitate is formed resulting in a tooth coloured appearance for the patient.

Tooth decay is one of the most common global health problems, with recent evidence suggesting that the incidence of tooth decay in some communities is a growing concern. Dental Health Services Victoria (DHSV) is currently undertaking a study on five hundred children who would normally be sent to hospital for general anaesthetic and severe extractions. Putting children under general anaesthetic is a potential health risk and a substantial cost to the public health system. The study by DHSV, using Riva Star, is assessing the ability for this product to reduce the need for hospital treatment. It is expected that the results of this study will be released later this year.

*"If the trial is successful, it will change the way we manage tooth decay in young children and reduce oral health inequity for those that are in most need," Dr Yawary said (Bite magazine, October 2017).*

Ms Samantha Cheetham, CEO commented "This product is an innovative preventative solution for the Company and adds to our leading position in the dental industry globally. At this stage we do not expect it to generate material sales in the short term, as more clinical studies and papers need to be completed from key opinion leaders in the dentistry profession; however, we believe that there will be strong global demand for this product, particularly in communities where dental care is unaffordable, therefore reducing the cost of Government assisted dental programs."

#### Investor Contact:

Adrian Mulcahy

[Adrian.mulcahy@marketeye.com.au](mailto:Adrian.mulcahy@marketeye.com.au)

P: +61 438 630 422

**SDI Limited** A.C.N. 008 075 581, A.B.N. 27 008 075 581

**Head Office** 3-13 Brunson St, Bayswater, P.O. Box 314, Victoria, 3153 Australia **Toll Free** 1 800 337 003 **T** +61 3 8727 7111 **F** +61 3 8727 7222  
**Info@sdi.com.au** [www.sdi.com.au](http://www.sdi.com.au) Offices and subsidiaries in Brazil, Germany, Ireland and the United States of America.